Q2 FY2026 EarningsQ2 FY26 performance significantly beat consensus across all key financial metrics, with revenue of $6.02M vs. $4.99M expected (+20.5%) and Diluted EPS of $0.11 vs. $0.01 expected. A one-time IEEPA tariff refund of $0.62M disproportionately boosted gross margin to 67.0%, compared to the 58.0% mean estimate. Despite programmatic growth in medical filtration, a reported material weakness in internal control over revenue recognition remains a critical governance overhang.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Nephros(NEPH) the Revenue is 6.017 M (+36.16%), Beat estimate;the EBIT is 1.213 M (+389.1%), Beat estimate;the EPS is 0.11 (+450%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B36.16%
0.00B13.00%
+0.00B23.16%
EBITExceed expectations
0.00B389.11%
0.00B83.87%
+0.00B472.98%
EPSExceed expectations
0.11450.00%
0.0150.00%
+0.1000500.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf